Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin FDC We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eris Lifesciences receives ANVISA approval for Ahmedabad Sterile Injectable facility We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eris Lifesciences Slapped Rs 17 Crore GST Notice Over Novartis Zomelis Deal We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eris Lifesciences on Monday said one of its manufacturing units in Ahmedabad has received approval from Brazil’s national health regulatory agency ANVISA. The approval follows a successful inspection conducted by the agency in May 2025, and enables the drugmaker to enter Brazil, the largest pharmaceutical market in South America, Eris Lifesciences said in a statement….
Eris Lifesciences, a leading branded formulations manufacturing company, reported a 41% year-on-year increase in net profit for the first quarter to Rs 125 crore, while revenue for the period stood at Rs 773 crore, an increase of 7.4% from the corresponding period last year. EBITDA for the first quarter stood at Rs 277 crore, up…
Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a “good” share of the market, Krishnakumar Vaidyanathan, executive director and chief operating…